15
Participants
Start Date
September 30, 2014
Primary Completion Date
March 31, 2018
Study Completion Date
May 31, 2021
Immune Globulin Subcutaneous (Human)
Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
USF Dept of Neurology, Tampa
Collaborators (1)
CSL Behring
INDUSTRY
University of South Florida
OTHER